Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:17:47 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Egetis Therapeutics - An Attractive Late-Stage Orphan Drug Play

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Egetis Therapeutics - An Attractive Late-Stage Orphan Drug Play

2021-02-16 08:00:00

Redeye raises its base case for Egetis by almost 60 percent after a closer look at the project pipeline following the merger with Rare Thyroid Therapeutics (RTT). In our view, the current valuation does not fully reflect the transformation into a late-stage orphan drug developer or the quality of the portfolio. We see a high likelihood that flagship project Emcitate could become the first approved treatment for MCT8 deficiency, an ultra-rare severe thyroid hormone disorder, and a potential USD 1bn+ market.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/